Abstract:BACKGROUND: The cleavage product of Raf-1 kinase inhibitor protein (RKIP), hippocampal cholinergic neurostimulating peptide (HCNP) is involved in the promotion of insulin secretion. Studies have shown that liraglutide can inhibit the progression of prediabetes. This study aims to investigate whether the above effects of liraglutide are related to RKIP and HCNP.METHODS: Insulin-1 (INS-1) cells were divided into control group (CON), HCNP group, and HCNP + darifenacin group (H-DAR). The three groups were cultured with Roswell Park Memorial Institute (RPMI) 1640, synthetic HCNP (50 pg/mL) and RPMI 1640, and HCNP + RPMI 1640 + darifenacin respectively. Subsequently, twelve 12- to 14-week-old Otsuka Long-Evans Tokushima Fatty (OLETF) rats were randomly divided into 2 groups: the placebo group (PBO) and the liraglutide treatment group (LIRA). Six Long Evans Tokushima Otsuka (LETO) rats were used as the control group (CON). The LIRA group was given liraglutide 200 µg/kg intraperitoneally twice a day. After 12 weeks, body weight, fasting blood glucose, 2 hours postprandial blood glucose, and insulin resistance index were recorded. Western blot was used to detect expression level of C-RKIP, N-RKIP, and extracellular signal-regulated kinase of phosphorylation (p-ERK). Real-time quantitative polymerase chain reaction (qRT-PCR) to detect pancreatic tissue choline acetyltransferase (ChAT) and M3 cholinergic receptor (M3R) gene expression levels.RESULTS: At glucose concentrations of 5.6 and 16.7 mmol/L, the insulin content in the HCNP group was higher than that in the CON and H-DAR groups (all P<0.01). The body weight and fasting serum insulin (FINS) of rats in the PBO group were higher than those in the LIRA group and the CON group (P<0.01). The relative content of C-RKIP protein in the PBO group was higher than that in the LIRA and CON groups (P<0.01). The relative content of N-RKIP protein and p-ERK protein was lower than that in the LIRA and CON group (P<0.05 and P<0.01, respectively). ChAT and M3R gene expression levels in PBO group were lower than those in LIRA and CON group (P<0.01).CONCLUSIONS: Liraglutide promotes the production of HCNP, can increase ChAT activity, activate M3R, and further promote the secretion of insulin.

The Akt/FoxO1/p27 Pathway Mediates the Proliferative Action of Liraglutide in Β Cells.

Protective Action of Liraglutide in Beta Cells Under Lipotoxic Stress Via PI3K/Akt/FoxO1 Pathway

Liraglutide Suppresses Proliferation and Induces Adipogenic Differentiation of 3T3-L1 Cells Via the Hippo-YAP Signaling Pathway

Liraglutide Enhances Glucose Transporter 4 Translocation Via Regulation of AMP-activated Protein Kinase Signaling Pathways in Mouse Skeletal Muscle Cells.

Effect and underlying mechanism of liraglutide on fibroblast growth factor-21 production in mouse islet β cells

GLP-1 Analog Liraglutide Enhances Proinsulin Processing in Pancreatic Β-Cells Via a PKA-dependent Pathway.

Liraglutide Protects Β-Cell Function by Reversing Histone Modification of Pdx-1 Proximal Promoter in Catch-Up Growth Male Rats.

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats.

Liraglutide Prevents Fast Weight Gain and Β-Cell Dysfunction in Male Catch-Up Growth Rats.

Glucagon-Like Peptide-1 Analog-Mediated Protection Against Cholesterol-Induced Apoptosis Via Mammalian Target Of Rapamycin Activation In Pancreatic Beta Tc-6 Cells

Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.

Role of glucagon-like peptide-1 analogue liraglutide played in the proliferation of CD4+ CD25-T cells in normal people and type 1 diabetic patients in vitro

Effect and mechanism of liraglutide on proliferation and apoptosis of human pancreatic cancer cells

Liraglutide protects palmitate-induced INS-1 cell injury by enhancing autophagy mediated via FoxO1

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats (Gato-Kakizaki大鼠使用利拉鲁肽进行早期干预可以保护胰腺β细胞): Liraglutide protects pancreatic beta cells in rats

Liraglutide Modulates Lipid Metabolism Via ZBTB20-LPL Pathway

Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein

Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic Β-Cell Regeneration in Situ in Type 1 Diabetic Mice

Glucagon-like Peptide 1 Receptor Agonist Ameliorates the Insulin Resistance Function of Islet Β Cells Via the Activation of PDX-1/JAK Signaling Transduction in C57/BL6 Mice with High-Fat Diet-Induced Diabetes

Liraglutide Reduces Lipogenetic Signals in Visceral Adipose of Db/db Mice with AMPK Activation and Akt Suppression